Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo.
about
RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptorsAdenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeDelivery of drugs bound to erythrocytes: new avenues for an old intravascular carrierRiboTag analysis of actively translated mRNAs in Sertoli and Leydig cells in vivo.Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expressionTargeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysisRecombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.Drug delivery by red blood cells: vascular carriers designed by mother nature.Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase.What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers.Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levelsFG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse.Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration.Minireview
P2860
Q24317297-1F95E302-D2EE-4C74-8F12-D6855EE344E4Q24563948-5C240612-C8ED-4B1D-84A1-A6FE90C03F12Q26801300-9736E727-A608-4E48-A4CE-9300CF5B9ADBQ27315140-A34E6B84-AFDB-4CC7-BB98-0E2CA5258CF5Q28575140-20B3E85E-D632-474E-9D7F-802F5078AD52Q33714889-731AF974-3D3B-419A-B9FA-C54AD9C6E053Q34017153-6D1723DB-7806-4B99-A19C-EE5CF0B485FCQ37397703-4854ACFC-C6F9-4626-9303-FA07BC88C1D5Q37700751-490C4BD6-750C-47EA-8FEB-3970D6EDB618Q38340653-D31066E2-33D7-4D98-A60F-DFD45DDDB610Q38392999-51554C18-0569-4CB6-B829-D88614D2F5F8Q40990270-EAA749E4-D142-4AD3-8C50-FE581A3FBB22Q42424619-E103176B-A221-4A74-8F02-A3EF23F30ECAQ48487114-8824B1D5-5952-4773-9AD9-EE103A6FFDC6Q52644622-35346551-2863-4D55-AAA3-23D0D70C8E93Q58883739-F8636A61-E343-4903-AEA4-D0431FA2284B
P2860
Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Two receptor systems are invol ...... ogen activator (t-PA) in vivo.
@ast
Two receptor systems are invol ...... ogen activator (t-PA) in vivo.
@en
type
label
Two receptor systems are invol ...... ogen activator (t-PA) in vivo.
@ast
Two receptor systems are invol ...... ogen activator (t-PA) in vivo.
@en
prefLabel
Two receptor systems are invol ...... ogen activator (t-PA) in vivo.
@ast
Two receptor systems are invol ...... ogen activator (t-PA) in vivo.
@en
P2093
P2860
P356
P1476
Two receptor systems are invol ...... ogen activator (t-PA) in vivo.
@en
P2093
P2860
P304
P356
10.1172/JCI118105
P407
P577
1995-08-01T00:00:00Z